Adage Capital Partners’s Apogee Therapeutics APGE Stock Holding History

Adage Capital Partners’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21M	Buy	250,000 +10,000	+4%	+$726K	0.03%	457
2025 Q4	$18.1M	Buy	240,000 +5,000	+2%	+$315K	0.03%	517
2025 Q3	$9.34M	Sell	235,000 -1,055,464	-82%	-$40.3M	0.01%	646
2025 Q2	$56M	Buy	1,290,464 +563,464	+78%	+$21.4M	0.09%	210
2025 Q1	$27.2M	Buy	727,000 +486,800	+203%	+$18.8M	0.05%	348
2024 Q4	$10.9M	Buy	+240,200	New	+$12.3M	0.02%	583
2024 Q3	–	Sell	-50,000	Closed	-$1.97M	–	871
2024 Q2	$1.97M	Sell	50,000 -125,000	-71%	-$6.07M	﹤0.01%	780
2024 Q1	$11.6M	Sell	175,000 -350,000	-67%	-$15.3M	0.02%	572
2023 Q4	$14.7M	Buy	525,000 +150,000	+40%	+$3.01M	0.03%	512
2023 Q3	$7.99M	Buy	+375,000	New	+$8.26M	0.02%	608

Other funds holding APGE

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Adage Capital Partners's APGE Position: Q1 2026 in Review

Adage Capital Partners increased its Apogee Therapeutics (APGE) stake by 4.2% in Q1 2026, buying an estimated $726K and bringing the position to 250,000 shares worth $21M. The position accounts for 0.03% of the portfolio, ranked #457.

Adage Capital Partners first reported a position in APGE in Q3 2023 and has held it in 10 quarters since. The position peaked at $56M in Q2 2025. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

Adage Capital Partners held 250,000 shares of Apogee Therapeutics worth $21M as of Q1 2026.
Adage Capital Partners bought 10,000 Apogee Therapeutics shares in Q1 2026, an estimated $726K.
Apogee Therapeutics made up 0.03% of Adage Capital Partners's portfolio in Q1 2026, its #457 holding.
Adage Capital Partners first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 10 quarters since.
Adage Capital Partners's Apogee Therapeutics position peaked at $56M in Q2 2025.
224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.